IDH1 and neoplasm: In fact, patients with histologically “low-grade” IDH-wildtype tumours that harbour EGFR amplification, +7/−10, or TERT promoter mutations demonstrate similar patient outcomes to those patients with IDH-wildtype tumours with high-grade histologic features [93,94,95].